论文部分内容阅读
卡米诺霉素(Карминомицин,简称КМ)是苏联1973年发现的一个新的蒽环类抗肿瘤抗生素。药理实验研究证明,它比阿霉素(Adria-mycin)心脏毒性低。临床证实对白血病和实体瘤都有较好的疗效,副作用也较少,在治疗中很少出现严重的血小板减少症。此外,该抗生素不影响免疫记忆的形成和T细胞的辅助功能,对机体免疫系统的某些功能有保护作用。临床上与甲基脲嘧啶合用可预防和降低心脏毒性。关于该抗生素的药理和临床报告甚多,本文重点简要地介绍1978年以后的研究进展情况。
Camicamycin (Карминомицин, referred to as КМ) is the Soviet Union in 1973 found a new anthracycline antitumor antibiotics. Pharmacological studies have shown that it is less cardiotoxic than Adria-mycin. Clinically proven leukemia and solid tumors have a good effect, fewer side effects, rarely severe thrombocytopenia in the treatment. In addition, the antibiotic does not affect the formation of immune memory and T cell helper functions, the body’s immune system has some function of protection. Clinically combined with methyl uracil can prevent and reduce cardiotoxicity. There are many pharmacological and clinical reports about this antibiotic. This article will briefly introduce the research progress after 1978.